CA - Roche: Obesity Treatment's Promise Isn't Enough
2024-06-25 17:50:06 ET
Summary
- Roche Holding AG stock has seen a 13% price rise in the past month following positive trial results for its obesity treatment.
- Weight management and associated diseases like diabetes have huge potential, as seen from the examples of Novo Nordisk and Eli Lilly, which focus on the segment.
- The treatment can be just the fillip Roche needs, considering its muted sales and earnings growth, as well as forecasts. But that will come later.
- For now, there's little upside remaining to the stock for 2024. And even though its dividend yield isn't bad, it's best to wait and watch for further developments.
The Swiss pharmaceutical stock Roche Holding AG ( OTCQX:RHHBY ) might have seen underwhelming performance year-to-date [YTD], but a turnaround is becoming visible with a 13% price rise in the past month. While the stock had already started inching up after touching five-year lows in early May, it got another boost following positive results for its weight management treatment....
Roche: Obesity Treatment's Promise Isn't Enough